General Dermatology

ICYMI, this week we had news about Ycanth's J-code launch, highlights from Diversity in Dermatology, bimekizumab's accepted sBLA for HS, and more.

Gil Yosipovitch, MD, discusses the correlation between increased BNP levels and chronic pruritus of unknown origin.

In a comparative study, benzyl benzoate demonstrated superior efficacy in scabies cases, while topical permethrin exhibited a lack of effectiveness.

Researchers reviewed the efficacy and safety of omalizumab in patients with severe CSU in a routine clinical practice setting.

This week’s collection of the latest dermatologic studies covers topical permethrin 5% vs. benzyl benzoate 25% for scabies, the safety of omalizumab in CSU during pregnancy, symptoms of cognitive impairment in children with AD, and the ethics of cosmetic overtreatment.

In this study, topical 0.1% retinol significantly improved crow’s feet, facial wrinkles, uneven skin tone, brown spots, and overall photoaging.

In this week’s Pointers With Portela, the 208SkinDoc reviews how the skin is affected during hormonal changes and menopause.

The new launch is set to bring berdazimer topical gel, 10.3% to adults and pediatric patients over the age of 1 with molluscum contagiosum faster.

The agreement for a second confirmatory trial comes after a successful phase 3 FLASH study that yielded positive outcomes and efficacy.

Shah discusses the science behind his products, as well as the challenges he didn’t anticipate when launching Remedy.

The biosimilar landscape experienced significant activity, marked by fresh data from conferences, novel findings regarding adalimumab biosimilars, and more.

Shahriari shares pearls and considerations from her sessions at the recent Diversity in Dermatology conference.

Povorcitinib is being evaluated for non-segmental vitiligo, hidradenitis suppurativa, prurigo nodularis, asthma, and chronic spontaneous urticaria.

The permanent J-code for the molluscum contagiosum treatment is now live.

ICYMI, this week we had news about bringing awareness to ethics in aesthetics, the 7 year anniversary of dupilumab's approval for atopic dermatitis, and more.

EltaMD representatives and dermatologists partook in the celebration on March 28 as a continuation of the celebration and momentum of the newly-established National Dermatologist Day.

Catch up on late-breaking research shared at the 2024 American Academy of Dermatology Annual Meeting.

Researchers from Google and Stanford Medicine recently partnered to develop the Skin Condition Image Network dataset, a tool aimed at providing image resources for conditions across skin tones.

In this week’s Pointers With Portela, the 208SkinDoc reveals his journey toward providing free dermatologic care through a mobile clinic.

We compare 2024 Match Day statistics with data from recent years.

Click here to answer today's poll and read more about recent uses of VR in dermatology education and practice.

Positive feelings accompanying BFRBs such as dermatillomania or trichotillomania may act as an important maintenance factor, researchers wrote.

Researchers analyzed the current treatment and research landscape for CLE in a review published in the Journal of Dermatology.

Researchers developed a VR scenario skin cancer screening involving technical realization, curricular integration, and an evaluation of the subjective learning experience and teaching concept.

Explore recent research that shed light on potential associations and manifestations post-COVID-19 infection or vaccination.

Dermatology Times recently spoke with Latanya Benjamin, MD, FAAD, FAAP, the newly-appointed president of the WDS, to discuss her hopes and goals for her presidency.

We spoke with several dermatology experts to gauge their thoughts on Valisure's recent findings of benzene in benzoyl peroxide products--as well as what actions they plan to take moving forward.

AI mobile apps have critical gaps in efficacy, safety, and transparency, according to a new report.

The FDA has assigned a Prescription Drug User Fee Act target action date for August 13.

On March 6, 2024, Valisure, an independent testing laboratory, found high levels of benzene when BPO products were incubated at 37°C, 50°C, and 70°C.